TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30247950

Group type: EXPERIMENTAL
Intervention: Mistletoe extracts (Helixor A, Iscador M Spez) injected three times per week during 18 weeks of chemotherapy
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 95
Study: 26784010

Group type: EXPERIMENTAL
Intervention: ACT-CL
Number of subjects: 234

Group type: COMPARATOR
Intervention: MHE
Number of subjects: 234
Study: 25147819

Group type: EXPERIMENTAL
Intervention: rilonacept
Number of subjects: 14

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study: 22848508

Group type: EXPERIMENTAL
Intervention: DRD2/ANKK1‐TaqIA A1‐allele status
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: DRD4 7R-allele status
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Group x DRD2/ANKK1‐TaqIA A1‐allele status interaction
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Group x DRD4 7R-allele status interaction
Number of subjects: 84
Study: 18684666

Group type: EXPERIMENTAL
Intervention: Pacifier use
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (non-users)
Number of subjects: 24
Study: 16968813

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both Pioglitazone and Metformin
Number of subjects: 0
Study: 15030987

Group type: EXPERIMENTAL
Intervention: 18 months combination therapy with interferon (3MU tiw) and ribavirin (1000-1200 mg/day)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 6 months combination therapy with interferon and ribavirin
Number of subjects: 300

Group type: COMPARATOR
Intervention: 18 months interferon combined with placebo
Number of subjects: 300
Study: 12383038

Group type: EXPERIMENTAL
Intervention: Sertraline (50-200 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sertraline (50-150 mg/day)
Number of subjects: 0
Study: 9661572

Group type: EXPERIMENTAL
Intervention: i.v. fluconazole 400 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: oral fluconazole 400 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study: 7663917

Group type: EXPERIMENTAL
Intervention: Bladder symptoms reported by teenagers at age 17
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: General decrease in frequency and intensity of symptoms from age 7 to 17
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: Desire for medical help regarding micturition disturbances
Number of subjects: 736
Study: 2528925

Group type: EXPERIMENTAL
Intervention: Sufentanil-nitrous oxide/oxygen anesthesia (S group)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Halothane-nitrous oxide/oxygen anesthesia (H group)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both groups (S and H)
Number of subjects: 44
Study: 4596632

Group type: EXPERIMENTAL
Intervention: Zinc sulphate administered for six weeks
Number of subjects: 65

Group type: COMPARATOR
Intervention: Healthy control subjects (two groups)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Patients with bronchial carcinoma
Number of subjects: 65
Study: 31124381

Group type: EXPERIMENTAL
Intervention: Cholecalciferol tablet 60,000 IU per week for 8 weeks
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 72
Study: 30868576

Group type: EXPERIMENTAL
Intervention: 5‐FU‐based preoperative chemoradiotherapy (CRT) alone or with oxaliplatin
Number of subjects: 1236

Group type: EXPERIMENTAL
Intervention: 5‐FU‐based preoperative chemoradiotherapy (CRT) with oxaliplatin
Number of subjects: 1236
Study: 28867602

Group type: EXPERIMENTAL
Intervention: Secnidazole 2 g
Number of subjects: 189

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study: 25082957

Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training
Number of subjects: 66

Group type: COMPARATOR
Intervention: Balance training
Number of subjects: 66
Study: 22483625

Group type: EXPERIMENTAL
Intervention: Early repolarization (ER) ≥ 0.1 mV in inferior and/or lateral leads
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: ER ≥ 0.1 mV and horizontal/descending ST variant (n=18)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: ER in inferior leads and horizontal/descending ST-segment variant
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Ascending ST variant
Number of subjects: 281
Study: 21557440

Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 470

Group type: COMPARATOR
Intervention: Neutral protamine hagedorn insulin
Number of subjects: 470
Study: 18664708

Group type: EXPERIMENTAL
Intervention: Feedback training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Familiarization training
Number of subjects: 0

Group type: COMPARATOR
Intervention: No training (Control group)
Number of subjects: 0
Study: 16687897

Group type: EXPERIMENTAL
Intervention: Initial resuscitation, appropriate antimicrobial treatment, selection of optimal control methods, properties of fluid therapy, use of vasopressors and inotropic therapy, proper corticosteroid administration, use of recombinant human activated protein C, glucose control
Number of subjects: 0
Study: 15273640

Group type: EXPERIMENTAL
Intervention: Cavit
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: IRM
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ultratemp Firm
Number of subjects: 45

Group type: COMPARATOR
Intervention: Negative Control (no restorative material, coated with sticky wax)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Positive Control (no restorative material, no sticky wax)
Number of subjects: 45
Study: 11677930

Group type: EXPERIMENTAL
Intervention: Filgrastim 375 micrograms s.c.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Filgrastim 750 micrograms s.c.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Filgrastim 375 micrograms i.v.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Filgrastim 750 micrograms i.v.
Number of subjects: 0
Study: 9206387

Group type: EXPERIMENTAL
Intervention: ALL-BOND 2
Number of subjects: 10

Group type: COMPARATOR
Intervention: Butler Protect
Number of subjects: 10
Study: 7961011

Group type: COMPARATOR
Intervention: Brachytherapy alone (18 patients)
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: External beam irradiation + brachytherapy (343 patients)
Number of subjects: 361

Group type: COMPARATOR
Intervention: T1T2 tumors (compared to T3)
Number of subjects: 361

Group type: COMPARATOR
Intervention: N0 tumors (compared to N+)
Number of subjects: 361

Group type: COMPARATOR
Intervention: Tumors with extension to the mobile tongue or base
Number of subjects: 361

Group type: COMPARATOR
Intervention: Total duration of treatment < 55 days
Number of subjects: 361

Group type: COMPARATOR
Intervention: Number of days between External Beam Irradiation and brachytherapy < 20
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Dose rate
Number of subjects: 361
Study: 3617198

Group type: EXPERIMENTAL
Intervention: Iron dextran prophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal or heterozygote groups
Number of subjects: 0
Study: 30093519

Group type: EXPERIMENTAL
Intervention: Arthroscopic-assisted balloon tibioplasty
Number of subjects: 80

Group type: COMPARATOR
Intervention: Open reduction internal fixation (ORIF)
Number of subjects: 80
Study: 26683985

Group type: EXPERIMENTAL
Intervention: Parent education brochure plus a student curriculum on the four recommended vaccines
Number of subjects: 686

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 686

Group type: COMPARATOR
Intervention: Parent education brochure
Number of subjects: 686
Study: 25530341

Group type: EXPERIMENTAL
Intervention: Cold pressor test
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (15 minutes bicycling at 75% VO2max)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control session (15 minutes quiet rest)
Number of subjects: 56
Study: 23873291

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day
Number of subjects: 1055

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1055
Study: 20960101

Group type: EXPERIMENTAL
Intervention: Glulisine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lispro
Number of subjects: 20
Study: 19731862

Group type: EXPERIMENTAL
Intervention: Itraconazole (administered to group A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No antimycotics (control group B)
Number of subjects: 0
Study: 16353228

Group type: EXPERIMENTAL
Intervention: Sonographically guided steroid injection (7 mg betamethasone and 0.5 ml of 1% lidocaine)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Palpation-guided steroid injection (7 mg betamethasone and 0.5 ml of 1% lidocaine)
Number of subjects: 25
Study: 14573329

Group type: EXPERIMENTAL
Intervention: 300 mg caffeine
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 10911415

Group type: EXPERIMENTAL
Intervention: 8 weeks of cast immobilization
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 10 weeks of supervised physical therapy
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (noninjured comparison subjects)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Plantar-flexor peak torque
Number of subjects: 10
Study: 8864313

Group type: EXPERIMENTAL
Intervention: 50 mg racemic ketoprofen
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 100 mg racemic ketoprofen
Number of subjects: 7
Study: 1551350

Group type: EXPERIMENTAL
Intervention: Alginic acid-antacid (extra-strength Gaviscon)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control antacid (equal acid-neutralizing capacity)
Number of subjects: 10
Study: 3158272

Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 370

Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 370
Study: 30584459

Group type: EXPERIMENTAL
Intervention: Polyphenol-rich herbal congee (D2 group, 1500 mg/day)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Polyphenol-rich herbal congee (D1 group, 50 mg/day)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 45
Study: 27662495

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment for 10 minutes at GV 26, Ex-HN 3, bilateral LI 4, and ST 36
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control session without acupuncture
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 14
Study: 24669147

Group type: EXPERIMENTAL
Intervention: Phacoemulsification (Group 1)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Manual Small-Incision Cataract Surgery (MSICS) (Group 2)
Number of subjects: 200
Study: 22004355

Group type: EXPERIMENTAL
Intervention: Drain inserted
Number of subjects: 272

Group type: COMPARATOR
Intervention: No drain
Number of subjects: 272
Study: 20720415

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy
Number of subjects: 509

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 509
Study: 18359648

Group type: EXPERIMENTAL
Intervention: Healthy-lifestyle (HL)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Diet (D)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Exercise (E)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Diet plus Exercise (D+E)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: All intervention groups combined
Number of subjects: 193
Study: 15950847

Group type: EXPERIMENTAL
Intervention: Intravenous hydroxyethyl starch (HES) 6% 200,000/0.5, 500 mL
Number of subjects: 40

Group type: COMPARATOR
Intervention: Electrolyte solution, 500 mL
Number of subjects: 40
Study: 12390336

Group type: EXPERIMENTAL
Intervention: High-level TSH suppression (0.4-0.6 mIU/ml)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Low-level TSH suppression (< or = 0.01 mIU/ml)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 49
Study: 10563539

Group type: EXPERIMENTAL
Intervention: Regular paper-filtered coffee (280 ml)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Warm water (280 ml)
Number of subjects: 15
Study: 7671515

Group type: EXPERIMENTAL
Intervention: Primary reamed intramedullary nailing
Number of subjects: 42

Group type: COMPARATOR
Intervention: Delayed reamed intramedullary nailing
Number of subjects: 42
Study: 2130173

Group type: EXPERIMENTAL
Intervention: Two-stage palatal closure (Unil-T) with primary veloplasty at 20 months and hard palate closure at 5 years 10 months
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Single-stage mucoperiosteal palatal push-back procedure (Unil-S)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Single-stage palatal closure (Bil-S)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Two-stage palatal closure (Bil-T)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (non-cleft subjects)
Number of subjects: 45
Study: 293922

Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 8

Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 8
Study: 31068654

Group type: EXPERIMENTAL
Intervention: tRNS (1.5 mA, 100-500 Hz)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 30
Study: 27435518

Group type: EXPERIMENTAL
Intervention: Elaborated inoculation
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Limited inoculation
Number of subjects: 340
Study: 26012232

Group type: EXPERIMENTAL
Intervention: Local anesthetic injected both SC and deep (GB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Local anesthetic injected subcutaneous (GA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline subcutaneous & deep (GC)
Number of subjects: 60
Study: 23378325

Group type: EXPERIMENTAL
Intervention: IM IFNβ‐1a
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study: 21429817

Group type: EXPERIMENTAL
Intervention: Iron and zinc tolerance test before surgery
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Iron and zinc tolerance test after surgery
Number of subjects: 9

Group type: COMPARATOR
Intervention: Iron and zinc tolerance test before and after surgery
Number of subjects: 9
Study: 19153001

Group type: EXPERIMENTAL
Intervention: Epirubicin (80 mg in 50 ml of saline) intravesically within 24 h of TUR
Number of subjects: 305

Group type: COMPARATOR
Intervention: No treatment after TUR
Number of subjects: 305
Study: 17578314

Group type: EXPERIMENTAL
Intervention: Pingchuan Yiqi Granule (PYG)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ruyi Dingchuan Pill (RDP)
Number of subjects: 80
Study: 11004346

Group type: EXPERIMENTAL
Intervention: Salivary estriol (E3) test at or above 2.1 ng/mL
Number of subjects: 956

Group type: EXPERIMENTAL
Intervention: Two consecutive positive salivary E3 tests
Number of subjects: 956

Group type: EXPERIMENTAL
Intervention: Salivary E3 test at or above 1.4 ng/mL
Number of subjects: 956
Study: 8988071

Group type: EXPERIMENTAL
Intervention: Ephedrine plus caffeine (20 mg ephedrine plus 200 mg caffeine three times a day)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Ephedrine plus caffeine
Number of subjects: 225

Group type: COMPARATOR
Intervention: Ephedrine plus caffeine and Placebo
Number of subjects: 225
Study: 1730189

Group type: EXPERIMENTAL
Intervention: Cefotaxime 1 g every 8 hr
Number of subjects: 74

Group type: COMPARATOR
Intervention: Ceftriaxone 1 g every 12 hr
Number of subjects: 74
Study: 6143505

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg sublingually, followed by 10 mg every 6 hours for a total of 24 hours)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 26
Study: 31460669

Group type: EXPERIMENTAL
Intervention: Concurrent opioids with benzodiazepines or nonbenzodiazepine sedatives (BZD-S)
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Opioids-only group
Number of subjects: 1500
Study: 30518044

Group type: EXPERIMENTAL
Intervention: NU-AGE diet group (dietary intervention for one year including 15 food groups and vitamin D supplement)
Number of subjects: 1296

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1296
Study: 27687032

Group type: EXPERIMENTAL
Intervention: Bromocriptine-QR (B-QR)
Number of subjects: 1791

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1791
Study: 24906074

Group type: EXPERIMENTAL
Intervention: Ground monitoring measurements and satellite aerosol optical depth (AOD) data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Speciation data analysis
Number of subjects: 0
Study: 22424012

Group type: EXPERIMENTAL
Intervention: Transendocardial injection of autologous aldehyde dehydrogenase-bright (ALDH(br)) cells
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no ALDH(br) cells)
Number of subjects: 20
Study: 20142410

Group type: COMPARATOR
Intervention: One course of adjuvant CVB chemotherapy for VASC- patients
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Two courses of adjuvant CVB chemotherapy for VASC+ patients
Number of subjects: 232

Group type: COMPARATOR
Intervention: Surveillance for VASC- patients
Number of subjects: 232

Group type: COMPARATOR
Intervention: Surveillance for VASC+ patients
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Adjuvant CVB chemotherapy (both groups)
Number of subjects: 232
Study: 19020146

Group type: EXPERIMENTAL
Intervention: Demand-only PCEA (5 mL bolus, 15 min lockout interval)
Number of subjects: 300

Group type: COMPARATOR
Intervention: PCEA with background infusion (5 mL/h, 5 mL bolus, 12 min lockout interval)
Number of subjects: 300

Group type: COMPARATOR
Intervention: PCEA with background infusion (10 mL/h, 5 mL bolus, 10 min lockout interval)
Number of subjects: 300
Study: 15840760

Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care (KMC)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Conventional Method of Care (CMC)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: KMC
Number of subjects: 123

Group type: COMPARATOR
Intervention: CMC
Number of subjects: 123
Study: 12432809

Group type: EXPERIMENTAL
Intervention: Dynamic spinal fixation system
Number of subjects: 155
Study: 10421228

Group type: EXPERIMENTAL
Intervention: TFA diet (5.1 E% trans fatty acids)
Number of subjects: 14

Group type: COMPARATOR
Intervention: MUFA diet (5.2 E% oleic acid)
Number of subjects: 14
Study: 7493430

Group type: EXPERIMENTAL
Intervention: Biosynthetic human growth hormone, subcutaneously, daily dose of 0.02-0.05 i.u./kg at bedtime
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control subjects with normal glucose tolerance
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hypopituitary patients with impaired glucose tolerance
Number of subjects: 40
Study: 2023447

Group type: EXPERIMENTAL
Intervention: Minitracheotomy postoperatively (Group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (Group B)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 31125576

Group type: EXPERIMENTAL
Intervention: Sorafenib-pravastatin combination (arm A)
Number of subjects: 323

Group type: COMPARATOR
Intervention: Sorafenib alone (arm B)
Number of subjects: 323
Study: 29565423

Group type: EXPERIMENTAL
Intervention: Whole-genome sequencing (WGS) report
Number of subjects: 200

Group type: COMPARATOR
Intervention: Family-history report alone
Number of subjects: 200
Study: 27287965

Group type: EXPERIMENTAL
Intervention: Neonatal Abstinence Scoring System (NASS; 'Finnegan Scale')
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: MOTHER NAS Scale (MNS)
Number of subjects: 131
Study: 25239828

Group type: EXPERIMENTAL
Intervention: Postprocedural anticoagulation for specific indications
Number of subjects: 2473

Group type: COMPARATOR
Intervention: No post-PCI anticoagulation
Number of subjects: 2473
Study: 22794223

Group type: EXPERIMENTAL
Intervention: K3 file system
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: WaveOne file system
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Self-Adjusting File (SAF)
Number of subjects: 30

Group type: COMPARATOR
Intervention: SAF as an adjunct after K3
Number of subjects: 30
Study: 20700793

Group type: EXPERIMENTAL
Intervention: Topical nipradilol
Number of subjects: 146

Group type: COMPARATOR
Intervention: Topical timolol
Number of subjects: 146
Study: 19203070

Group type: EXPERIMENTAL
Intervention: ACE‐inhibitor quinaprilat 0.5 mg/h administered intravenously via infusion pump
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (standard inotropic‐vasodilator therapy)
Number of subjects: 70
Study: 15708700

Group type: EXPERIMENTAL
Intervention: NT-proBNP levels measured at randomization and at 48 hours, 6 weeks, 3 months, and 6 months.
Number of subjects: 1216

Group type: EXPERIMENTAL
Intervention: NT-proBNP levels predictive of two-year mortality.
Number of subjects: 1216

Group type: EXPERIMENTAL
Intervention: Factors associated with higher reduction rates of NT-proBNP levels.
Number of subjects: 1216

Group type: EXPERIMENTAL
Intervention: Factors associated with lower reduction rates of NT-proBNP levels.
Number of subjects: 1216
Study: 11861525

Group type: EXPERIMENTAL
Intervention: PPARγ agonists (chronic treatment for 11 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (14-day treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metformin or PPARα agonist (treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Severe insulin resistance patients (dominant-negative PPARγ mutations)
Number of subjects: 0
Study: 10491246

Group type: EXPERIMENTAL
Intervention: Multimedia educational intervention (handout about ADs + videotape about ADs + procedural aspects and outcomes of CPR)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group (handout about ADs)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Multimedia educational intervention
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 117
Study: 7488811

Group type: EXPERIMENTAL
Intervention: Budesonide (inhaled steroid)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 2030065

Group type: EXPERIMENTAL
Intervention: Bruce treadmill protocol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Balke treadmill protocol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Field exercise trial (800-m run)
Number of subjects: 30
Study: 7046724

Group type: EXPERIMENTAL
Intervention: Meditation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Biofeedback
Number of subjects: 30